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Periconceptional folic acid use can often prevent neural tube defects (NTDs). Variants of
genes involved in folate metabolism in mothers and children have been associated with
occurrence of NTDs. We identified Irish families with individuals affected by neural tube
defects. In these families, we observed that neural tube defects and birth defects overall
occurred at a higher rate in the maternal lineage compared with the paternal lineage.
The goal of this study was to look for evidence for genetic effects that could explain
the discrepancy in the occurrence of these birth defects in the maternal vs. paternal
lineage. We genotyped blood samples from 322 individuals from NTD-affected Irish
families, identified through their membership in spina bifida associations. We looked for
differences in distribution in maternal vs. paternal lineages of five genetic polymorphisms:
the DHFR 19bp deletion, MTHFD1 1958G>A, MTHFR 1298A>C, MTHFR 677C>T, and
SLC19A1 80A>G. In addition to looking at genotypes individually, we determined the
number of genotypes associated with decreased folate metabolism in each relative
(“risk genotypes”) and compared the distribution of these genotypes in maternal vs.
paternal relatives. Overall, maternal relatives had a higher number of genotypes associated
with lower folate metabolism than paternal relatives (p = 0.017). We expected that
relatives would share the same risk genotype as the individuals with NTDs and/or their
mothers. However, we observed that maternal relatives had an over-abundance of any
risk genotype, rather than one specific genotype. The observed genetic effects suggest
an epigenetic mechanism in which decreased folate metabolism results in epigenetic
alterations related to the increased rate of NTDs and other birth defects seen in the
maternal lineage. Future studies on the etiology of NTDs and other birth defects could
benefit from including multigenerational extended families, in order to explore potential
epigenetic mechanisms.
Keywords: neural tube defects, folate metabolism, DHFR 19bp deletion, MTHFD1 1958G>A, MTHFR 1298A>C,
MTHFR 677C>T, SLC19A1 80A>G, maternal inheritance
INTRODUCTION
Neural tube defects (NTDs) are congenital anomalies of the brain
and spinal cord that cause significant morbidity and mortality
(Sutton et al., 2008). Historically, Ireland has had high rates of
NTDs (Coffey, 1983), with rates decreasing significantly in the
last 50 years (Botto et al., 2006). Both environmental and genetic
factors have been implicated in the etiology of NTDs. The evi-
dence for environmental factors lies in the protective effect of
periconceptional folic acid intake (Czeizel and Dudas, 1992). The
evidence for genetic factors lies in the increased recurrence risk in
siblings of individuals with NTDs, the increased risk for NTDs
among other relatives, and the increased risk for birth defects
overall among both close and distant relatives (MRC Vitamin
Study Research Group, 1991; Deak et al., 2008). Maternal relatives
have higher NTD and overall birth defect rates than paternal rel-
atives, consistent with a combination of genetic and epigenetic
mechanisms contributing to NTD and overall birth defects risk
(Byrne et al., 1996; Byrne, 2008, 2010, 2011; Deak et al., 2008).
The genetic mechanisms associated with NTDs have been
addressed through studies on associations between NTD risk and
variants in genes involved in folate metabolism, chosen because
of the protective effect of folic acid on NTDs (Molloy et al.,
2009; Shaw et al., 2009). Methylene tetrahydrofolate reductase
(MTHFR) plays an important role in folate metabolism. The 677
T allele results in reduced enzyme activity and decreased folate
metabolism (Frosst et al., 1995). The MTHFR 677 TT geno-
type in infants and mothers has been associated with increased
risk for NTDs [reviewed in Botto and Yang (2000)]. Studies
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in Irish populations found significantly more individuals with
NTDs with the TT and CT genotypes and more parents of
affected individuals with the TT genotype (Whitehead et al., 1995;
Shields et al., 1999; Kirke et al., 2004; Carter et al., 2011). The
MTHFR 1298A>C variant also results in reduced enzyme activity,
although its role in NTD risk is less clear (van der Put et al., 1998;
Botto and Yang, 2000;Wang et al., 2012a). Parle-McDermott et al.
(2003) did not find an association between theMTHFR 1298A>C
variant and NTDs in an Irish population. Methylene tetrahydro-
folate dehydrogenase 1 (MTHFD1) acts in folate metabolism and
DNA synthesis, and the 1958G>A variant results in decreased
enzyme stability (Christensen et al., 2009). Studies in Irish pop-
ulations (Brody et al., 2002; Parle-McDermott et al., 2006) iden-
tified a significant excess of MTHFD1 AA homozygotes among
mothers of NTD cases compared to controls. A recent larger scale
study in an Irish population also identified the MTHFD1 A allele
as a risk factor for NTDs (Pangilinan et al., 2012). Dihydrofolate
reductase (DHFR) also acts in folate metabolism. Studies have
yielded conflicting results on the effect of the 19 bp deletion
at intron 1 on red blood cell folate concentrations (Kalmbach
et al., 2008; Stanislawska-Sachadyn et al., 2008). Researchers from
Trinity College in Dublin observed a slight protective effect of
the homozygous DHFR deletion genotype in mothers (Parle-
McDermott et al., 2007). SLC19A1 plays an important role in
folate transport, and some previous studies have reported associ-
ations between the 80A>G variant and NTD risk (Chango et al.,
2000; De Marco et al., 2003; Wang et al., 2012b). O’Leary et al.
(2006) did not find a difference in the frequency of the SLC19A1
80A>G reduced folate carrier in mothers, fathers and affected
individuals compared with controls in an Irish population.
Epigenetic mechanisms related to NTDs have not been well
explored. The higher rates of NTDs in maternal relatives com-
pared with paternal relatives suggest the presence of epigenetic
effects. Folate metabolism genes are of interest because folate
metabolism is critical to the production of one-carbon sub-
units needed for epigenetic modification (Crider et al., 2012).
Decreased folate metabolism, seen with certain gene variants,
might hinder proper establishment or maintenance of epigenetic
modifications. The epigenetic changes of interest would occur in
the maternal genome in utero, that is, during the grandmother’s
pregnancy (Crider et al., 2012). Thus, in contrast to genetic mech-
anisms, in which the mothers’ and affected individuals’ genotypes
would be most relevant, for epigenetic mechanisms, the mater-
nal and paternal grandparents’ genotypes would be important.
In the absence of information on grandparents’ genotypes, aunts,
uncles, and first cousins provide an indirect measure of the
grandparents’ genotypes.
In this hypothesis-generating study, we investigated possible
mechanisms for the excess risk for NTDs and birth defects over-
all in the maternal lineage of Irish individuals with NTDs. To do
this, we evaluated five polymorphisms in genes involved in folate
metabolism in the maternal vs. paternal lineage, both individually
and with low folate-metabolizing genotypes grouped together. To
our knowledge, this study is the first to look for genomic asso-
ciations in extended relatives in NTD families and the effect of
maternal vs. paternal lineage risk. We chose five polymorphic
markers for evaluation, which were among the most intensely
studied so far: the 19 bp deletion in DHFR, MTHFD1 1958G>A,
MTHFR 1298A>C, MTHFR 677C>T, and SLC19A1 80A>G.
MATERIALS AND METHODS
STUDY DESIGN AND PARTICIPANTS
The participants in this cross-sectional study were members
of Irish families with NTDs. These families had previously
participated in epidemiologic studies of the Boyne Research
Institute [for instance, (Byrne, 2011)]. The families were iden-
tified initially through their membership in the Louth-Meath
(northeastern region of the Republic of Ireland) branch of the
Irish Association for Spina Bifida and Hydrocephalus, and the
Ballymena (Northern Ireland) branch of the (UK) Association
for Spina Bifida and Hydrocephalus. Families were also recruited
through word of mouth and through radio announcements in the
Louth-Meath area.
To be eligible for the study, male and female participants had
to be 15 years of age or older, reside in the northeast region of
the Republic of Ireland or Northern Ireland, and be either the
individual with an NTD (only one NTD in sibship) or a blood rel-
ative of the affected individual. In terms of relationship, relatives
(defined according to their relationship to the affected individual)
had to be one of the following: parents, siblings, nieces, nephews,
offspring (of the affected individual), grandparents, uncles, aunts,
first cousins and first cousins once removed (the offspring of the
first cousins).
Family members were interviewed in phases. Phase I evalu-
ated pregnancy histories and the health of siblings in the original
nuclear families (1995–2002). Phase II subjects (uncles and aunts
of the affected individuals) were identified by their siblings during
Phase I and interviewed between 2000 and 2002. Phase III con-
sisted of interviews with first cousins of the affected individuals
(the children of the uncles and aunts) between 2002 and 2009.
Between 2005 and 2006, affected individuals and their siblings
were interviewed.
For the present study, conducted in 2007, the response rate
among eligible, locatable relatives was 49.5%, or 331 participants.
From these, 322 gave a blood sample. Of these with a blood sam-
ple, 34 were relatives in families in which the individual with
an NTD had anencephaly, 41 in which the affected individual
had spina bifida occulta, 240 in which the affected individual
had open spina bifida and 7 in which the affected individual had
encephalocele.
This study was conducted according to the guidelines from
the Declaration of Helsinki and all procedures involving human
subjects were approved by the Ethics Board of the Boyne
Research Institute and the Ethics Committee of the Health Service
Executive of the Irish Government’s Department of Health
and Children. Written informed consent was obtained from all
subjects.
STATISTICAL ANALYSIS
Data weremanaged usingMicrosoft EXCEL©, and statistical anal-
ysis was conducted using SAS 9.1 (SAS Institute, Cary, NC, USA),
STATA©, and IBM® SPSS® v19. Measures of association were
evaluated with t-tests for continuous variables and chi-square
and Fisher’s exact tests for categorical variables, with the level of
Frontiers in Genetics | Epigenomics and Epigenetics November 2013 | Volume 4 | Article 223 | 2
Fisk Green et al. Folate gene variants in families
statistical significance set at 0.05. First-degree relatives were par-
ents, siblings, and children; second-degree relatives were aunts,
uncle, nieces, nephews, and grandparents; and third-degree and
higher relatives were cousins and first cousins once removed.
Genotypes were analyzed using an additive model, consistent
with previous studies. For logistic regression analyses, genotypes
were dichotomized using a recessive model, consistent with pre-
vious studies. For each individual, we calculated the number of
“risk genotypes” present. “Risk genotypes” were those associated
with lower folate metabolism in previous studies (DHFRWT/WT,
MTHFD1 1958 AA, MTHFR 1298 CC, MTHFR 677 TT, and
SLC19A1 80 GG).
DNA METHODS
DNA was extracted from blood clots using Gentra Puregene
Blood kit and Clotspin Baskets per manufacturer’s protocol
(Qiagen, Valencia, CA). Quantitation was performed by spec-
trophotometric reading at 260nm and all samples normalized
to 10 ng/µl. For PCR reactions, 2µl genomic DNA (20 ng)
was used. Pyrosequencing technology (Qiagen, Valencia, CA)
was used to genotype DNA samples for DHFR 19bp dele-
tion (rs70991108), MTHFD1 1958G>A (rs2236225), MTHFR
1298A>C (rs1801131), MTHFR 677C>T (rs1801133), and
SLC19A1 80A>G (rs1051266). PCR and pyrosequencing primers
(Table 1) were designed using PSQAssay Design Software Version
1.0.6. After amplification, the pyrosequencing primer was used
to extend the PCR product by addition of nucleotides in a spe-
cific sequential order based on the known sequence. The resulting
pyrogram of signal peaks was used to determine the genotype.
PCR amplification for the DHFR 19bp deletion was performed
using the GC Rich PCR System (Roche, Indianapolis, IN) as
previously described (Parle-McDermott et al., 2007). PCR for
all other variants was performed in a 20µl reaction mix con-
taining 0.5µM each forward and reverse primer and Applied
Biosystems GeneAmp® Fast PCR Master Mix. Amplification was
performed using the 9800 Fast PCR System according to man-
ufacturer’s suggested protocol (Applied Biosystems, Foster City,
CA). Pyrosequencing was carried out as described by manufac-
turer’s protocol (Qiagen, Valencia, CA).
QUALITY CONTROL
Five percent of the samples were selected at random for repeat
testing of the five polymorphisms, and the concordance was
checked. We also tested each variant for any significant departure
from Hardy-Weinberg equilibrium (HWE) by a chi-square
goodness-of-fit test to verify data quality. In addition, Mendelian
inheritance for all variants was assessed in 13 families with full
trios using the PedCheck program (O’Connell and Weeks, 1998).
Water and genotype controls (Coriell Cell Repositories, Camden,
NJ) were included on each assay plate. The tests for HWE indi-
cated that none of the variants deviated significantly from HWE,
supporting high quality genotype data. All replica test results were
100% concordant.
RESULTS
We obtained blood samples from all categories of relatives,
including individuals with NTDs (n = 13), offspring (N = 2),
fathers (N = 29), mothers (N = 37), siblings (N = 59), nieces
and nephews (N = 2), uncles and aunts (N = 66), first cousins
(N = 105), and grandparents (N = 2) from 47 families. Paternal
relatives (N = 65) and maternal relatives (N = 115) comprised
uncles and aunts, first cousins, first cousins once removed, and
grandparents, who were related to the affected individual through
the father and mother, respectively. The average age of the study
participants was 41 years. The overall distribution of each of the
five polymorphisms is shown in Table 2. The genotype distribu-
tions for the five polymorphisms in our study were similar to
those from other studies, with a few exceptions (Table 3).
ANALYSIS OF INDIVIDUAL POLYMORPHISMS
The distributions of each genotype and allele by relationship to
the individual with an NTD, degree of relationship to the affected
individual, andmaternal vs. paternal lineage are shown inTable 4.
We did not observe any significant associations between individ-
ual genotypes and the affected individuals or mothers, although
the higher folate-metabolizing MTHFR 677 CC genotype tended
to be found less often in affected individuals (15.4%) than in all
other relatives (42.7%) (Fisher’s exact test, p = 0.08) (Table 4 and
data not shown). We also did not see any significant associations
between individual genotypes and maternal vs. paternal lineage
(Table 4).
Relatives of individuals with NTDs might be expected to
have genotypes associated with increased or decreased risk for
NTDs, and the prevalence of these genotypes could increase or
decrease with degree of closeness to the affected individual. For
MTHFR 1298A>C, a lower percentage of first-degree relatives
(34.6%) had the higher folate-metabolizing AA genotype com-
pared with second-degree (50.0%) relatives and third-degree and
Table 1 | Primer sequences and PCR amplicon size for DHFR,MTHFD1,MTHFR, and SLC19A1 variant analysis.
Variant Forward primer (5′–3′)a Reverse primer (5′–3′)a Sequencing primer (5′–3′)b Amplicon
size (bp)
DHFR 19bp deletion (rs70991108) CAAGAACGGGGACCTGCC *ATCCTCTCGCCGGGAGTC GCCCACGGTCGGGGT 114,133
MTHFD1 1958G>A (rs2236225) TCATTTTGCTTAGAGCACAGTAGA *CATCCACTTTCCTGGCTTAAAT CACAGTAGAGAGTGCCAA 63
MTHFR 1298A>C (rs1801131) GGAGCTGCTGAAGATGTGG *TGGTTCTCCCGAGAGGTAAAG AGGAGCTGACCAGTGA 85
MTHFR 677C>T (rs1801133) *ATTGGCAGGTTACCCCAAAGG TCGGTGCATGCCTTCACAA CGTGATGATGAAATCG 156
SLC19A1 80A>G (rs1051266) *GTGGAACCTGGGCCTGAC GTAGGGGGTGATGAAGCTCTC CAAAGGTAGCACACGA 114
a*Biotinylated at 5′ end.
bRepresent forward primers for DHFR, MTHFD1, MTHFR 1298, and reverse primers for MTHFR 677 and SLC19A1.
cMTHFR 677 and SLC19A1 assays on reverse complement strand.
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Table 2 | Characteristics of the participants, northeast region of the
Republic of Ireland and Northern Ireland, 1995–2009.
Range Median
Age in years Overall 16–86 41.5
Affected individual 18–47 28.8
1st degree 17–73 44.7
2nd degree 18–86 52.1
3rd degree or higher 16–59 33.5
N %
Gender Males 120 37.3
Females 202 62.7
Relationship Affected individual 13 4.0






First cousin 105 32.6
First cousin once removed 7 2.2
Grandfather 1 0.3
Grandmother 1 0.3
1st degree 127 39.4
2nd degree 70 21.7
3rd degree or higher 112 34.8




















Line Paternal relatives 65 36.0
Maternal relatives 115 64.0
higher (53.6%) relatives (p = 0.009). Similarly, the A allele was
less common in first-degree relatives (61.4%) than in second-
degree relatives (70.0%) and third-degree and higher (73.7%)
relatives (p = 0.005). When the genotype (AA vs. A/C, C/C)
and relatives (first-degree relatives vs. all other relatives) were
dichotomized, the odds ratio for the association of the AA geno-
type with first-degree relatives was 0.49 (0.30–0.78, p = 0.002)
(data not shown). Consistent with this, a lower percentage of sib-
lings, 30.5%, had the AA genotype compared to 48.3% among
other relatives (p = 0.04, Table 4). We did not observe a consis-
tent trend of genotypes being more or less common in relatives
more closely related to the affected individual for any of the other
genotypes (Table 4).
We observed some associations with individual categories of
relatives. For example, fewer first cousins had the higher folate-
metabolizing DHFR del/del genotype compared with all other
relatives (12.4 vs. 22.1%, p = 0.11, Table 4 and data not shown),
the higher folate-metabolizingMTHFD1GG genotype was higher
in uncles and aunts compared with all other relatives (51.5 vs.
31.6%, p = 0.003) (Table 4), and the lower folate-metabolizing
SLC19A1 GG genotype was more common in uncles and aunts
than in other relatives (42.4 vs. 26.6%, p = 0.04) (Table 4).
However, the meaning of these isolated associations is unclear.
NUMBER OF RISK GENOTYPES
While the frequencies of individual genotypes did not differ sig-
nificantly between maternal and paternal relatives (Table 4), the
number of risk genotypes, defined as the number of homozy-
gous genotypes associated with lower folate metabolism, did
show significant variation between the maternal and paternal
lines (p = 0.02) (Table 5). A lower percentage of maternal rela-
tives (20.9%) had no (0) risk genotypes compared with paternal
relatives (41.5%), while more maternal relatives (54.8%) than
paternal relatives (35.4%) had 1 risk genotype. When the risk
genotypes were dichotomized (0, 1–3), the odds ratio for associ-
ation with the maternal line compared with the paternal line was
2.69 (1.38–5.25, p = 0.004).
The numbers of risk genotypes in affected individuals and
mothers (p = 0.004) or mothers alone (p = 0.005), compared
with all other relatives were also statistically significant (Table 5).
A higher percentage of affected individuals and mothers (30.0
vs. 17.3%) and mothers alone (32.4 vs. 17.5%) had 2 risk geno-
types compared with all other relatives, while a lower percentage
of affected individuals and mothers (22.0 vs. 47.8%) and mothers
alone (18.9 vs. 47.1%) had 1 risk genotype. A higher percentage
of affected individuals and mothers (44.0 vs. 31.6%) and mothers
alone (46.0 vs. 31.9%) had 0 risk genotypes.
DISCUSSION
In the Irish families in our study, we found that maternal relatives
were more likely than paternal relatives to have one or more geno-
types associated with decreased folate metabolism. As expected
from previous studies, mothers and affected individuals had dif-
ferential distributions of risk genotypes compared with all other
relatives.
The observed increased number of affected relatives in the
maternal lineage of families could be due to genetic and/or epi-
genetic mechanisms. A simple genetic explanation would be that
more maternal relatives have alleles associated with increased risk
for NTDs simply due to chance, so the likelihood of inheriting
these alleles from the maternal side would be increased. With a
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Table 3 | Distribution of genotypes and comparison with other studies.
DHFR Del/Del Del/WT WT/WT P
N % N % N %
This study Ireland, NTD relatives 61 18.9 172 53.5 89 27.6 Ref.
Parle-McDermott et al., 2007 Ireland, controls 46 18.6 128 51.8 73 29.6 0.88
Kalmbach et al., 2008 US, unaffected 216 17.1 646 51.4 396 31.5 0.39
This study Ireland, mothers 7 18.9 22 59.5 8 21.6 Ref.
Parle-McDermott et al., 2007 Ireland, mothers 49 18.0 130 47.0 96 35.0 0.25
MTHFD1 A/A A/G G/G
This study Ireland, NTD relatives 51 15.7 156 48.6 115 35.7 Ref.
HapMap (CEU) Utah 20 17.7 54 47.8 39 34.5 0.90
Parle-McDermott et al., 2006 Ireland, controls 150 19.5 411 53.4 209 27.1 0.02
This study Ireland, Mothers 8 21.6 17 46.0 12 32.4 Ref.
Parle-McDermott et al., 2006 Ireland, mothers 65 27.0 118 48.0 62 25.0 0.62
MTHFR 1298 A/A A/C C/C
This study Ireland, NTD relatives 145 45.0 147 45.7 30 9.3 Ref.
HapMap (CEU) Utah 49 43.4 51 45.1 13 11.5 0.79
van der Put et al., 1998 Holland, controls 179 44.4 186 46.2 38 9.4 0.99
Mills et al., 2008 Ireland, controls 519 49.4 439 41.8 92 8.8 0.38
MTHFR 677 C/C C/T T/T
This study Ireland, NTD relatives 134 41.6 156 48.6 32 9.8 Ref.
HapMap (CEU) Utah 53 47.0 50 44.2 10 8.8 0.62
Shields et al., 1999 Ireland, controls 114 47.1 108 44.6 20 8.3 0.41
Mynett-Johnson et al., 2002 Ireland, unaffected volunteers 209 34.7 299 49.7 94 15.6 0.02
This study Ireland, affected individuals 2 15.4 9 69.2 2 15.4 Ref.
Shields et al., 1999 Ireland, affected individuals 101 37.3 119 43.9 51 18.8 0.18
This study Ireland, mothers 17 46.0 18 48.6 2 5.4 Ref.
Shields et al., 1999 Ireland, mothers 80 36.7 108 49.5 30 13.8 0.29
SLC19A1 A/A A/G G/G
This study Ireland, NTD relatives 58 18.0 168 52.2 96 29.8 Ref.
HapMap (CEU) Utah 18 16.0 62 55.4 32 28.6 0.83
O’Leary et al., 2006 Ireland, controls 103 27.0 179 47.0 99 26.0 0.02
This study Ireland, affected individuals 4 30.8 7 53.9 2 15.3 Ref.
O’Leary et al., 2006 Ireland, affected individuals 61 23.0 131 50.0 72 27.0 0.60
This study Ireland, mothers 7 18.9 19 51.4 11 29.7 Ref.
O’Leary et al., 2006 Ireland, mothers 65 25.0 119 45.0 80 30.0 0.70
This study Ireland, fathers 7 24.1 16 55.2 6 20.7 Ref.
O’Leary et al., 2006 Ireland, fathers 58 22.0 127 48.0 79 30.0 0.58
simple genetic model, we would expect that relatives would share
the same risk genotype as the affected individuals and/or moth-
ers. However, we did not observe this, but instead found that
maternal relatives had an over-abundance of any risk genotype,
rather than one specific genotype. We found that more mater-
nal relatives had one risk genotype, while more paternal relatives
had no risk genotypes. However, if this were the main explana-
tion behind the increased number of affected individuals on the
maternal side, we would expect that relatives more closely related
to the affected individuals would share more genetic risk factors,
and thus the prevalence of higher risk genotypes would be greater
in first-degree relatives than in more distant ones. However, with
the exception ofMTHFR 1298, we did not observe consistent pat-
terns of increasing numbers of risk genotypes with closer degree
of relationship to the affected individual.
The mother’s genotype during pregnancy plays a significant
role in NTD risk, best studied in MTHFR (Yan et al., 2012), and
the inheritance of these alleles would necessarily come from the
maternal line. In this case, mothers and possibly affected indi-
viduals might be expected to have an increased prevalence of
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Table 4 | Distribution of genotypes and alleles according to relationship within NTD-affected families and lineage, northeast region of the
Republic of Ireland and Northern Ireland, 1995–2009.
DHFR Genotype frequencies Pb Allele frequencies Pb
Del/Del Del/WT WT/WT Del WT
N % N % N % N % N %
Affected individual 2 15.4 6 46.2 5 38.4 0.74 10 38.5 16 61.5 0.45
Mother 7 18.9 22 59.5 8 21.6 0.66 36 48.6 38 51.4 0.58
Father 6 20.7 15 51.7 8 27.6 0.97 27 46.6 31 53.4 0.89
Sibling 13 22.0 35 59.3 11 18.7 0.23 61 51.7 57 48.3 0.13
Uncle/aunt 16 24.2 30 45.5 20 30.3 0.30 62 47.0 70 53.0 0.71
First cousin 13 12.4 61 58.1 31 29.5 0.11 87 41.4 123 58.6 0.13
Other rel. 4 30.8 3 23.0 6 46.2 0.06 11 42.3 15 57.7 0.73
1st degree relatives 26 20.5 72 56.7 29 22.8 0.36 124 48.8 130 51.1 0.23
2nd degree relatives 17 24.3 33 47.1 20 28.6 0.36 67 47.9 73 52.1 0.61
3rd degree or higher relatives 16 14.3 61 54.5 35 31.2 0.20 93 41.5 131 58.5 0.10
Paternal linea 9 13.8 37 56.9 19 29.3 0.40 55 42.3 75 57.7 0.65
Maternal linea 24 20.9 55 47.8 36 31.3 103 44.8 127 55.2
MTHFD1 G/G G/A A/A G A
Affected individual 2 15.4 8 61.5 3 23.1 0.24 12 46.2 14 53.8 0.14
Mother 12 32.4 17 46.0 8 21.6 0.59 41 55.5 33 44.6 0.40
Father 14 48.3 10 34.5 5 17.2 0.26 38 65.5 20 34.5 0.36
Sibling 16 27.2 32 54.2 11 18.6 0.31 64 54.2 54 45.8 0.16
Uncle/aunt 34 51.5 28 42.4 4 6.1 0.003 96 72.7 36 27.3 0.0008
First cousin 34 32.4 53 50.5 18 17.1 0.68 121 57.6 89 42.4 0.40
Other rel. 3 23.1 8 61.5 2 15.4 0.55 14 53.8 12 46.2 0.52
1st degree relatives 43 33.9 60 47.2 24 18.9 0.36 146 57.5 108 42.5 0.20
2nd degree relatives 35 50.0 30 42.9 5 7.1 0.01 100 71.4 40 28.6 0.003
3rd degree or higher relatives 35 31.2 58 51.8 19 17.0 0.34 128 55.4 96 42.9 0.20
Paternal line 23 35.4 36 55.4 6 9.2 0.24 82 63.1 48 36.9 0.93
Maternal line 47 40.9 50 43.5 18 15.6 144 62.6 86 37.4
MTHFR 1298 A/A A/C C/C A C
Affected individual 6 46.2 6 46.2 1 7.6 1.00 18 69.2 8 30.8 0.88
Mother 15 40.5 17 46.0 5 13.5 0.61 47 63.5 27 36.5 0.40
Father 11 37.9 15 51.8 3 10.3 0.72 37 63.8 21 36.2 0.49
Sibling 18 30.5 35 59.3 6 10.2 0.04 71 60.2 47 39.8 0.05
Uncle/aunt 33 50.0 26 39.4 7 10.6 0.52 92 69.7 40 30.3 0.61
First cousin 54 51.4 44 41.9 7 6.7 0.22 152 72.4 58 27.6 0.09
Other rel. 8 61.5 4 30.8 1 7.7 0.49 20 76.9 6 23.1 0.31
1st degree relatives 44 34.6 68 53.6 15 11.8 0.009 156 61.4 98 38.6 0.005
2nd degree relatives 35 50.0 28 40.0 7 10.0 0.56 98 70.0 42 30.0 0.53
3rd degree or higher relatives 60 53.6 45 40.2 7 6.2 0.05 165 73.7 59 26.3 0.02
Paternal line 30 46.3 29 44.5 6 9.2 0.53 89 68.5 41 31.5 0.27
Maternal line 63 54.8 44 38.2 8 7.0 170 73.9 60 26.1
MTHFR 677 C/C C/T T/T C T
Affected individual 2 15.4 9 69.2 2 15.4 0.09 13 50.0 13 50.0 0.08
Mother 17 46.0 18 48.6 2 5.4 0.59 52 70.3 22 29.7 0.39
Father 11 37.9 15 51.7 3 10.4 0.91 37 63.8 21 36.2 0.73
Sibling 22 37.3 34 57.6 3 5.1 0.19 78 66.1 40 33.9 0.95
Uncle/aunt 32 48.5 28 42.4 6 9.1 0.44 92 69.7 40 30.3 0.29
First cousin 44 41.9 47 44.8 14 13.3 0.33 135 64.3 75 35.7 0.56
(Continued)
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Table 4 | Continued
Genotype frequencies Pb Allele frequencies Pb
N % N % N % N % N %
Other rel. 6 46.2 5 38.5 2 15.3 0.60 17 65.4 9 34.6 0.96
1st degree relatives 52 40.9 67 52.8 8 6.3 0.14 171 67.3 83 32.7 0.72
2nd degree relatives 34 48.6 30 42.9 6 8.5 0.53 98 70.0 42 30.0 0.32
3rd degree or higher relatives 46 41.1 50 44.6 16 14.3 0.12 142 63.4 82 36.6 0.22
Paternal line 33 50.8 26 40.0 6 9.2 0.38 92 70.8 38 29.2 0.16
Maternal line 47 40.9 52 45.2 16 13.9 146 63.5 84 36.5
SLC19A1 A/A A/G G/G A G
Affected individual 4 30.8 7 53.9 2 15.3 0.32 15 57.7 11 42.3 0.15
Mother 7 18.9 19 51.4 11 29.7 0.99 33 44.6 41 55.4 0.93
Father 7 24.1 16 55.2 6 20.7 0.45 30 51.7 28 48.3 0.22
Sibling 11 18.6 35 59.4 13 22.0 0.34 57 48.3 61 51.7 0.31
Uncle/aunt 11 16.7 27 40.9 28 42.4 0.04 49 37.1 83 62.9 0.07
First cousin 16 15.2 56 53.4 33 31.4 0.66 88 41.9 122 58.1 0.44
Other rel. 2 15.4 8 61.5 3 23.1 0.93 12 46.2 14 53.8 0.83
1st degree relatives 25 19.7 72 56.7 30 23.6 0.09 122 48.0 132 52.0 0.06
2nd degree relatives 11 15.7 30 42.9 29 41.4 0.07 52 37.1 88 62.9 0.08
3rd degree or higher relatives 18 16.0 59 52.7 35 31.3 0.88 95 42.4 129 57.6 0.67
Paternal line 12 18.5 34 52.3 19 29.2 0.40 58 44.6 72 55.4 0.21
Maternal line 17 14.8 53 46.1 45 39.1 87 37.8 143 62.2
aPaternal line consists of uncles and aunts, grandparents, first cousins and first cousins once removed who are related to the affected individual through the father;
maternal line consists of uncles and aunts, grandparents, first cousins and first cousins once removed who are related to the affected individual through the mother.
bFor specific relatives, each category was compared with all other relatives to calculate P-values. For example, fathers were compared with all other relatives to
calculate the P-value. For degree of relationship to the affected individual, each category was compared with a combination of the other two to calculate the P-value.
For example, 1st degree relatives were compared with 2nd and 3rd degree relatives combined to calculate the P-value. P-values were calculated using a chi-square
test unless one or more cells contained less than 5, in which case Fisher’s exact test was used.
Table 5 | Number of risk genotypes by relationship to affected individuals with NTDs and lineage, northeast region of the Republic of Ireland
and Northern Ireland, 1995–2009.
Number of risk genotypes/low metabolizer genotypes P-valuea (Fisher’s exact test)
0 1 2 3
N % N % N % N %
Maternal line 24 20.9 63 54.8 24 20.9 4 3.4 0.02
Paternal line 27 41.5 23 35.4 12 18.5 3 4.6
Affected individual or mother 22 44.0 11 22.0 15 30.0 2 4.0 0.004
All other relatives 86 31.6 130 47.8 47 17.3 9 3.3
Mother 17 46.0 7 18.9 12 32.4 1 2.7 0.005
All other relatives 91 31.9 134 47.1 50 17.5 10 3.5
aP-values compare maternal vs. paternal line, affected individual or mother vs. all other relatives, and mother vs. all other relatives.
genotypes associated with greater NTD risk. In our study, fewer
affected individuals had the higher folate-metabolizing MTHFR
677 CC genotype, consistent with earlier reports that the homozy-
gous TT genotype is a risk factor for NTDs (Shields et al.,
1999; Botto and Yang, 2000). Likewise, affected individuals and
mothers, as well as mothers only, were more likely to have 2
risk genotypes. Our study of these associations was limited by
our small sample size and was not the main objective of this
study. While our findings were consistent with previous litera-
ture, these associations alone were not strong enough to explain
the increased number of affected relatives on the mother’s side,
suggesting that other mechanisms are also at work.
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Whenever there is preferential inheritance of a condition from
the maternal vs. paternal line, epigenetic effects are strongly
suspected. The genes included in our study are not located in
known imprinted regions. However, folate metabolism is critical
to the production of one-carbon subunits needed for epigenetic
modification. Certain variants of folate metabolism genes (pos-
sibly including those in our study), which are associated with
NTD risk, might affect proper imprinting and establishment
or maintenance of other epigenetic changes. These epigenetic
effects could occur in the maternal genome and would have
been initiated when the mother was a fetus herself, but may
also have taken place in the genomes of the mother’s parents
(Crider et al., 2012). If this mechanism were at work, the maternal
and paternal grandparents’ genotypes would be of importance.
Unfortunately, we were unable to obtain samples from many
grandparents. However, aunts, uncles, and first cousins provide
an indirect measure of the grandparents’ genotypes, and sig-
nificant associations for these relatives were seen for DHFR,
MTHFD1, and SLC19A1. The increased number of risk genotypes
in maternal vs. paternal relatives is consistent with an epigenetic
mechanism.
Our study is the first to look at the genotypes of second- and
third-degree or more relatives in families affected by NTDs and to
begin to explore the genetic and epigenetic mechanisms behind
the increased NTD and overall birth defects risks in these fam-
ilies. However, our study is preliminary and has a number of
limitations. The limitations of our study include a relatively small
sample size, lack of triads (both parents and offspring) among
distant relatives to allow for heritability testing, and inadequate
number of samples from grandparents to evaluate epigenetic
effects. Additionally, more maternal than paternal relatives par-
ticipated in the study. However, while this might have affected the
stability of the point estimate for the association of risk genotypes
with the maternal vs. paternal line, it did not affect the magni-
tude or direction. The response rate was relatively low for our
study, and the participation of families and of relatives within
families could be biased and not reflect the true underlying dis-
tribution of families with NTDs in Ireland. However, selection
for and participation in the study was independent of genotype
and thus participants can be considered close to a random sample
of relatives. The candidate gene approach used here evaluated a
small number of polymorphisms and would have missed associ-
ations with other variants in folate metabolism pathway genes.
An important limitation of our study (and others) is that we
were not able to measure the mother’s intake of folate and folic
acid during pregnancy. The genes included in this study function
in folate metabolism, so that their effect depends on the levels
of folate present in the body. For example, high intake of folic
acid and folate could mask genetic effects that would be seen at
lower intake levels. Lastly, the number of multiple comparisons
evaluated in our study likely produced some spurious findings.
Our results are consistent with both genetic and epigenetic
mechanisms contributing to the increased NTD and overall birth
defects risk in the maternal lineage. The diversity of genetic risk
seen in these families suggests that etiology of NTDs is multi-
faceted. Future studies will benefit from including other relatives,
especially grandparents, in addition to mothers, fathers, and
affected individuals, especially if epigenetic mechanisms are to be
addressed.
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